Chemiluminescence immunoassay (CLIA) technology is emerging as a critical infrastructure layer for the functional foods and nutraceutical sector, as the global CLIA market is projected to reach $16.39 billion by 2031, according to new analysis from MarketsandMarkets. The growth trajectory reflects accelerating demand for high-sensitivity diagnostic testing and automated laboratory systems — tools increasingly relied upon by supplement brands to substantiate structure-function claims through measurable clinical endpoints.
CLIA platforms detect trace-level biomarkers — including hormones, cytokines, and inflammatory markers — at sensitivities that older enzyme-linked immunoassay (ELISA) formats cannot consistently achieve. For ingredient suppliers and finished-formulation brands commissioning double-blind, placebo-controlled trials, CLIA's precision translates directly into the ability to detect statistically significant changes in endpoints such as cortisol, C-reactive protein, insulin-like growth factor-1, or 25-hydroxyvitamin D. That analytical resolution matters enormously when a trial is designed to support a peer-reviewed publication or an FDA-reviewed structure-function claim dossier.
The nutraceutical industry's growing investment in clinical substantiation is converging with this diagnostic buildout. Consumer trust in supplement efficacy has pushed brands toward biomarker-backed validation rather than self-reported outcomes alone, a shift that is particularly visible in categories like adaptogens and stress response and micronutrient sufficiency testing. Retailers and health-system buyers increasingly require clinical data packages before authorizing shelf placement or formulary inclusion, making access to automated, high-throughput immunoassay infrastructure a competitive differentiator for contract research organizations serving the supplement industry.
Laboratory automation — a key demand driver cited in the MarketsandMarkets report — also has downstream implications for ingredient standardization. Standardized extracts and finished formulations that cite specific mg/serving doses of bioactive compounds depend on validated assay methods for both raw material verification and clinical outcome measurement. As CLIA instruments become more widely deployed in contract laboratory networks, the cost and turnaround time associated with biomarker-based clinical trials for nutraceuticals are expected to decline, potentially opening rigorous trial design to mid-market brands that previously lacked the budget for high-sensitivity biomarker panels.
For operators sourcing ingredients with GRAS status or pursuing New Dietary Ingredient (NDI) notifications, the broader immunoassay market expansion signals a maturing analytical ecosystem that can support more granular safety and efficacy documentation. The Food & Beverage Magazine network has tracked similar convergence between diagnostic technology investment and nutraceutical claim substantiation across probiotic CFU quantification and other dose-verification disciplines. As the CLIA market scales toward $16.39 billion by 2031, functional ingredient brands that build relationships with CLIA-equipped CROs now are likely to hold a measurable validation advantage in an increasingly evidence-oriented retail and regulatory environment.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.